(5 years, 9 months ago)
Commons ChamberWill the Minister update us on what steps are being taken to support recently liberated areas in Iraq?
Significant ones. I was in Iraq two weeks ago and met the new President of Iraq, and its Prime Minister and Foreign Minister. Iraq knows that it must complete its introductory reconstruction efforts. It is important that those who have been abandoned in the Nineveh plain are able to get back, but the security situation remains crucial. Only when there is a strong security situation, organised and controlled by the state, will it be safe for everyone to go back. The United Kingdom is playing a leading part to encourage and support the efforts to promote reconstruction and the safety of those who have been displaced.
(6 years, 2 months ago)
Commons ChamberThe International Development Committee, which is led by the hon. Member for Liverpool, West Derby (Stephen Twigg), questioned me about that just a few weeks ago. We have details on the counselling and support that is being provided. The tragedy is that this will need to go on for some time. It seems likely that those in the camps will not be able to return soon. What is essential—the hon. Lady’s question is helpful in relation to this—is that the eye of the world does not go off this matter. The funding for the support that is needed must not be lost and people must not forget the Rohingya who are in the camps.
A large number of vulnerable Rohingya women and children still live in Rakhine province. What humanitarian assistance are the Government providing to those vulnerable women and girls?
My hon. Friend is correct: there is difficulty in gaining access to the Rakhine province. It has been possible for humanitarian agencies to get into only some of the province. We have sought to reshape our programme to make sure that more support is available to those who are still in Rakhine, and it should not be forgotten that they remain in a very vulnerable position.
(9 years, 1 month ago)
Commons ChamberThe guidance says that in treating their patients, clinicians must first consider using a licensed medicine within its licensed indication. If that will not meet their patient’s needs, they can consider a licensed medicine outside its licensed indication, and only if that is not suitable should they consider using a medicine that is not licensed at all. We know that a great many medicines can offer benefits to patients when prescribed outside their licensed indications.
Not at the moment, because this point is absolutely crucial to put on the record.
Prescribing in that way is part and parcel of normal, everyday clinical practice, as the hon. Member for Central Ayrshire confirmed. It is very common in prescribing for children and in treating some forms of pain. Most doctors, particularly GPs, will do it every day in their clinical practice. That has already been covered in relation to tamoxifen and raloxifene for the prevention of familial breast cancer. As was rightly identified by the hon. Member for Torfaen, the issue is compounded when drugs come off patent and new evidence suggests that they would be appropriate in the treatment of new indications.
The hon. Gentleman has gathered a lot of support for the Bill, but it does give the impression that such drugs are not being made available to patients. It also suggests that licensing is required to make these drugs available for patients, and that a NICE technology appraisal is required as well.
The reason I said earlier that I would go on until 2.30 and beyond is that I have not even begun to deal with the licensing arguments and the problems—[Interruption.] Hon. Members just said that I had run out of arguments, but I have not even covered the difficulty of the Secretary of State being put in the position of being the regulator and someone who applies for licences. There are plenty more arguments that need to be put and I think that we will run out of time.
Given the Minister’s clear support for the principles behind the Bill, will he agree to meet the various organisations to see whether there is a non-legislative means of achieving the aims of the Bill?
I am certain that the Under-Secretary of State for Life Sciences will meet people soon at my request to carry on our discussion. It is clear that the House is not in any way comfortable with the Government’s position in resisting this Bill, so before the matter is considered again it is essential that the Government look at it further. If a message had gone out from the House that there was only one way for people to get access to the drugs they need, that would be wrong—